TD Waterhouse Canada Inc. Buys 1,192 Shares of Cencora, Inc. (NYSE:COR)

TD Waterhouse Canada Inc. raised its stake in Cencora, Inc. (NYSE:COR) by 1.5% during the fourth quarter, HoldingsChannel.com reports. The fund owned 79,853 shares of the company’s stock after purchasing an additional 1,192 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Cencora were worth $17,941,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of COR. Passumpsic Savings Bank increased its holdings in shares of Cencora by 4.9% in the third quarter. Passumpsic Savings Bank now owns 6,464 shares of the company’s stock worth $1,455,000 after purchasing an additional 304 shares during the last quarter. Virtu Financial LLC boosted its stake in Cencora by 112.2% during the third quarter. Virtu Financial LLC now owns 10,227 shares of the company’s stock valued at $2,302,000 after buying an additional 5,407 shares during the last quarter. World Investment Advisors LLC purchased a new position in Cencora during the 3rd quarter valued at approximately $4,072,000. Arvest Bank Trust Division bought a new stake in Cencora in the 3rd quarter worth approximately $218,000. Finally, Wilmington Savings Fund Society FSB purchased a new stake in shares of Cencora during the 3rd quarter worth approximately $566,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

Shares of COR stock opened at $281.32 on Tuesday. The company’s 50-day simple moving average is $264.76 and its two-hundred day simple moving average is $247.76. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. Cencora, Inc. has a one year low of $214.77 and a one year high of $296.65. The company has a market capitalization of $54.55 billion, a P/E ratio of 40.02, a P/E/G ratio of 1.31 and a beta of 0.55.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, equities analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were issued a $0.55 dividend. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.78%. Cencora’s dividend payout ratio is presently 31.29%.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on COR. Wells Fargo & Company boosted their price target on shares of Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a research report on Friday, March 14th. Bank of America upped their target price on shares of Cencora from $270.00 to $285.00 and gave the company a “neutral” rating in a research report on Friday, April 11th. Evercore ISI boosted their price objective on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. StockNews.com upgraded Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. Finally, Morgan Stanley set a $288.00 target price on Cencora in a report on Tuesday, April 15th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $284.55.

Insider Transactions at Cencora

In related news, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares of the company’s stock, valued at $3,724,197.76. This represents a 24.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Chairman Steven H. Collis sold 14,578 shares of Cencora stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the completion of the transaction, the chairman now directly owns 317,913 shares in the company, valued at $85,680,732.63. This represents a 4.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 30,675 shares of company stock valued at $8,034,778. Corporate insiders own 10.80% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.